(19)
(11) EP 3 126 841 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.09.2019 Bulletin 2019/37

(45) Mention of the grant of the patent:
03.07.2019 Bulletin 2019/27

(21) Application number: 15717821.1

(22) Date of filing: 31.03.2015
(51) International Patent Classification (IPC): 
G01N 33/569(2006.01)
G01N 33/68(2006.01)
G01N 33/92(2006.01)
(86) International application number:
PCT/EP2015/056977
(87) International publication number:
WO 2015/150360 (08.10.2015 Gazette 2015/40)

(54)

BIOMARKERS FOR ASSESSING HIV

BIOMARKER ZUR BEURTEILUNG VON HIV

BIOMARQUEURS POUR ÉVALUER LE VIH


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 04.04.2014 EP 14001259

(43) Date of publication of application:
08.02.2017 Bulletin 2017/06

(73) Proprietors:
  • IDCGS Clinica de Diagnosticos Medicos
    04117-000 Sao Paulo (BR)
  • Diaz, Ricardo Sobhie
    Santana de Parnaíba - SP 06519-332 (BR)
  • BIOCRATES Life Sciences AG
    6020 Innsbruck (AT)

(72) Inventors:
  • DA SILVA, Ismael Dale Cotrim Guerreiro
    04117-000 Sao Paulo - SP (BR)
  • LOTURCO, Edson Guimaraes
    04117-000 Sao Paulo - SP (BR)
  • DIAZ, Ricardo Sobhie
    04025-014 Sao Paulo - SP (BR)
  • KOAL, Therese
    A-6020 Innsbruck (AT)

(74) Representative: Ter Meer Steinmeister & Partner 
Patentanwälte mbB Nymphenburger Straße 4
80335 München
80335 München (DE)


(56) References cited: : 
EP-A1- 2 284 540
WO-A1-94/05814
   
  • KIRMSE BRIAN ET AL: "Abnormal Newborn Screens and Acylcarnitines in HIV-exposed and ARV-exposed Infants", PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 32, no. 2, February 2013 (2013-02), pages 146-150, XP008172444,
  • VILASECA M A ET AL: "Low serum carnitine in HIV-infected children on antiretroviral treatment.", EUROPEAN JOURNAL OF CLINICAL NUTRITION OCT 2003, vol. 57, no. 10, October 2003 (2003-10), pages 1317-1322, XP055143674, ISSN: 0954-3007
  • ZANGERLE R ET AL: "Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy", BRAIN, BEHAVIOR AND IMMUNITY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 24, no. 3, 1 March 2010 (2010-03-01), pages 403-408, XP026908256, ISSN: 0889-1591, DOI: 10.1016/J.BBI.2009.11.004 [retrieved on 2009-11-16]
  • ROBERT ZANGERLE ET AL: "Effective Antiretroviral Therapy Reduces Degradation of Tryptophan in Patients with HIV-1 Infection", CLINICAL IMMUNOLOGY, vol. 104, no. 3, 1 September 2002 (2002-09-01), pages 242-247, XP055158992, ISSN: 1521-6616, DOI: 10.1006/clim.2002.5231
  • GERARD WONG ET AL: "Plasma Lipidomic Profiling of Treated HIV-Positive Individuals and the Implications for Cardiovascular Risk Prediction", PLOS ONE, vol. 9, no. 4, 14 April 2014 (2014-04-14), page e94810, XP055159090, DOI: 10.1371/journal.pone.0094810
  • J. CONSTANS ET AL: "Fatty acids and plasma antioxidants in HIV-positive patients: Correlation with nutritional and immunological status", CLINICAL BIOCHEMISTRY, vol. 28, no. 4, 1 August 1995 (1995-08-01) , pages 421-426, XP055159419, ISSN: 0009-9120, DOI: 10.1016/0009-9120(95)00017-4
  • Welma Oosthuizen ET AL: "Polyunsaturated fatty acid intake is adversely related to liver function in HIV-infected subjects: the THUSA study 1-3", , 1 May 2006 (2006-05-01), XP055159418, Retrieved from the Internet: URL:http://ajcn.nutrition.org/content/83/5 /1193.full.pdf [retrieved on 2014-12-18]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).